The CAPRIE trial: Culmination of the preregistration program for clopidogrel

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 2, 1999, Pages 1-2

  Gent, Michael ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLEEDING; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; RASH; SHORT SURVEY; THROMBOSIS;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 0032814255     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (2)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106